Oncology-New York最新文献

{"title":"Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.","authors":"Coral Omene","doi":"10.46883/2026.25921238","DOIUrl":"10.46883/2026.25921238","url":null,"abstract":"<p><p>Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.","authors":"José Luis Rodríguez-Olivares, Mauricio Mora Pineda Md, Evelyn Beas-Lozano, Alec Seidman-Sorsby Md, Yuly A Remolina-Bonilla, Armando Gamboa-Domínguez Md, Jeffrey Weitzel Md Facmg, Pedro Barata Md MSc, Yanin Chavarri-Guerra Md MSc Fasco, María T Bourlon","doi":"10.46883/2026.25921234","DOIUrl":"https://doi.org/10.46883/2026.25921234","url":null,"abstract":"<p><p>This cross-sectional study evaluated the genetic landscape of a cohort of patients with metastatic prostate cancer who were treated at a referral center in Mexico City, Mexico.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance.","authors":"Nora Janjan","doi":"10.46883/2026.25921214","DOIUrl":"10.46883/2026.25921214","url":null,"abstract":"<p><p>A primary driver of skyrocketing health care budgets has been the cost of prescription medications, which is particularly true for oncology, as personalized medicine is the standard of care.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 5","pages":"220-222"},"PeriodicalIF":2.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis.","authors":"Irgen Tafaj, Oksana Allko, Liri Cuko","doi":"10.46883/2026.25921197","DOIUrl":"https://doi.org/10.46883/2026.25921197","url":null,"abstract":"<p><p>We describe a unique clinical case of primary melanoma of the ascending colon presenting with intussusception and profuse hemorrhage. A 72-year-old man on anticoagulant therapy was admitted with massive rectal bleeding and hypotension. Colonoscopy revealed an 8-cm obstructing exophytic tumor. CT scan confirmed enteroenteric intussusception via the pathognomonic pseudokidney sign. Diagnosis was established by immunohistochemical analysis, demonstrating positive expression of S100 protein and melanoma-associated antigens, while negative for melanocyte antigen A and BRAF mutations. The patient underwent emergency right-sided hemicolectomy with lymphadenectomy. Pathomorphological evaluation confirmed stage T4aN0M0 (R0 resection). Following an accelerated recovery protocol, the patient started adjuvant immunotherapy with PD-1 inhibitors. This case underscores the need for a multidisciplinary approach and extended immunohistochemical profiling to diagnose rare mucosal pathologies. It highlights the effectiveness of radical surgery combined with modern systemic immunotherapy in emergency settings. Given the aggressive nature of mucosal melanoma, adhering to oncological guidelines and considering early immunotherapy are crucial for optimizing clinical outcomes.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 5","pages":"197-203"},"PeriodicalIF":2.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma.","authors":"Hala Soomro, Amninder Singh, Mohammad Ahsen Soomro, Kuldeepsinh Atodaria, Peter Khalil, Muhammad Hamza Gul, Zekra Ehsaan","doi":"10.46883/2026.25921198","DOIUrl":"https://doi.org/10.46883/2026.25921198","url":null,"abstract":"<p><p>In this retrospective cohort study, it was shown that acute pancreatitis hospitalizations occurred more frequently in patients with multiple myeloma who were older and more medically complex.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 5","pages":"208-211"},"PeriodicalIF":2.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.","authors":"Carmel Awadallah, Anas Zayad","doi":"10.46883/2026.25921166","DOIUrl":"10.46883/2026.25921166","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T-cell therapies have transformed the management of hematologic malignancies, including relapsed/refractory multiple myeloma (RRMM), lymphomas, and leukemias. These approaches enable targeted cytotoxicity through T-cell redirection and engineered cellular activity, achieving high response rates in heavily pretreated populations. Data presented at the 2025 Immune Cell Effector Therapies (ICE-T) Symposium highlighted expansion beyond B-cell maturation antigen (BCMA) to additional targets such as GPRC5D and FcRH5, alongside emerging multitarget and next-generation constructs aimed at improving durability and overcoming resistance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This narrative review summarizes key findings from the 2025 ICE-T Symposium, integrating data from clinical trials, real-world studies, and contemporary guideline-based management, with a focus on efficacy, safety, sequencing, and emerging therapeutic platforms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Across hematologic malignancies, immune-based therapies demonstrated substantial and clinically meaningful activity, with outcomes varying by disease subtype, target antigen, and therapeutic platform. In multiple myeloma, BCMA-directed bispecific antibodies, including teclistamab and elranatamab, achieved overall response rates (ORRs) of approximately 63% and 61%, respectively, in heavily pretreated populations, with median progression-free survival (PFS) of approximately 11 to 17 months across pivotal studies. Talquetamab demonstrated ORR of approximately 73% to 74% in the MonumenTAL-1 study (NCT03399799), supporting efficacy in post-BCMA settings. Cevostamab has shown promising early-phase activity, with response rates of approximately 55% to 60% at higher dose levels, reflecting the expansion of therapeutic targets beyond BCMA. In B-cell lymphomas, CD19-directed CAR T-cell therapies, including axicabtagene ciloleucel and lisocabtagene maraleucel, produced high response rates with durable remissions in relapsed/refractory large B-cell lymphoma, with long-term follow-up demonstrating sustained survival in a subset of patients. Among bispecific antibodies, epcoritamab achieved an ORR of approximately 60% to 65%, whereas glofitamab demonstrated an ORR of approximately 45% to 50% in heavily pretreated populations, supporting their role as effective off-the-shelf therapeutic options. In acute lymphoblastic leukemia, CD19-directed CAR T-cell therapies, including tisagenlecleucel and brexucabtagene autoleucel, achieved high rates of remission with deep measurable residual disease negativity, supporting their role as definitive or bridging strategies in relapsed disease. Beyond hematologic malignancies, early-phase data highlighted the expansion of T cell-redirecting therapies into solid tumors. The DLL3-directed bispecific antibody tarlatamab demonstrated clinically meaningful activity in relapsed small ce","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?","authors":"Nora Janjan","doi":"10.46883/2026.25921073","DOIUrl":"10.46883/2026.25921073","url":null,"abstract":"<p><p>The affordability of health care will be the top issue in the upcoming midterm elections. However, the discussion about health care affordability began more than 15 years ago with the passage of the Affordable Care Act (ACA), which was dubbed Obamacare. Under the ACA, every American was to have health insurance and access to care. Citing PolitiFact, Mark Memmott of National Public Radio in December 2013 reported that President Barack Obama told the \"lie of the year,\" publicly claiming more than 35 times that \"if you like your health care plan, you can keep it.\" The ACA was also supposed to allow patients to \"keep their doctor\" and save each family of 4 about $2500 per year, which never occurred.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 3","pages":"178-179"},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Before Certainty.","authors":"Yan Leyfman","doi":"10.46883/2026.25921074","DOIUrl":"10.46883/2026.25921074","url":null,"abstract":"<p><p>A young father faces a potential lymphoma diagnosis, revealing how medical language, restraint, and rapid coordination reshape care and ease uncertainty.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.","authors":"Michał Kostrzanowski, Adam Górski, Grzegorz Panek, Grzegorz Ziółkowski, Agata Mandes, Filip Dąbrowski","doi":"10.46883/2026.25921071","DOIUrl":"10.46883/2026.25921071","url":null,"abstract":"<p><p>The term synchronous refers to 2 or more primary independent malignancies, when the second (or subsequent) arises within 6 months after diagnosis of the first malignancy. Synchronous endometrial and ovarian cancers are found in 10% of patients with ovarian cancer and 5% of patients with endometrial cancer. Using a variety of criteria, pathologists can distinguish synchronous primary tumors from metastatic disease. Primary surgical staging remains the gold standard for treating patients with synchronous endometrial and ovarian cancers. Adjuvant therapy is still controversial in the early stages of the disease. Genetic evaluation of patients with a positive family history may be crucial for quicker diagnosis and to identify those with familial cancer syndrome. We present the case of a 47-year-old premenopausal woman with abdominal pain who qualified for surgery due to suspicion of an ovarian tumor during a physical examination and imaging studies. After the final histopathologic examination, the patient was diagnosed with synchronous endometrial cancer, FIGO IA, and ovarian cancer, FIGO IIIC stage .</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 3","pages":"172-175"},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.","authors":"Mu'taz Dreidi, Imad Asmar, Mahmoud Ayayda","doi":"10.46883/2026.25921070","DOIUrl":"10.46883/2026.25921070","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent malignancy among women and frequently causes significant psychological distress, such as anxiety and depression. The perception and impact of social support in addressing these mental health challenges differ depending on cultural and societal factors, highlighting its crucial role.</p><p><strong>Aim: </strong>This study aimed to evaluate the association between anxiety and depression in Palestinian women with breast cancer and perceived social support (PSS).</p><p><strong>Methods: </strong>A descriptive, cross-sectional design was employed. The study included 257 patients with breast cancer. Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale. PSS was measured using the Medical Outcomes Study Social Support Survey.</p><p><strong>Results: </strong>Most participants (95%) were married. The mean age was 51 ± 9.8 years. The total PSS was relatively mild to moderate (M = 69.7 ± 9.5). The scores for anxiety and depression were in the borderline range(M = 7.8 ± 3.3 and M = 8.3 ± 3.6, respectively). All subclasses of PSS were negatively correlated with anxiety and depression ( P < .05).</p><p><strong>Conclusion: </strong>Every individual has a unique perception of social support. Depression and anxiety affect a sizable percentage of patients with breast cancer. Higher levels of social support may also assist in reducing depression and anxiety, as seen by the strong negative association found between these psychological states and PSS.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 3","pages":"165-171"},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}